{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:02:05Z","timestamp":1788825725533,"version":"build-2803163510"},"reference-count":38,"publisher":"The Society for Free Radical Research Japan","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Clin. Biochem. Nutr."],"published-print":{"date-parts":[[2022]]},"DOI":"10.3164\/jcbn.21-104","type":"journal-article","created":{"date-parts":[[2021,11,4]],"date-time":"2021-11-04T22:11:56Z","timestamp":1636063916000},"page":"64-71","source":"Crossref","is-referenced-by-count":20,"title":["The anti-inflammatory and protective role of interleukin-38 in inflammatory bowel disease"],"prefix":"10.3164","volume":"70","author":[{"given":"Masashi","family":"Ohno","sequence":"first","affiliation":[{"name":"Department of Medicine, Shiga University of Medical Science"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Imai","sequence":"additional","affiliation":[{"name":"Department of Medicine, Shiga University of Medical Science"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoharu","family":"Chatani","sequence":"additional","affiliation":[{"name":"Department of Medicine, Shiga University of Medical Science"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Nishida","sequence":"additional","affiliation":[{"name":"Department of Medicine, Shiga University of Medical Science"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Inatomi","sequence":"additional","affiliation":[{"name":"Department of Medicine, Shiga University of Medical Science"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Kawahara","sequence":"additional","affiliation":[{"name":"Department of Medicine, Shiga University of Medical Science"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoaki","family":"Hoshino","sequence":"additional","affiliation":[{"name":"Division of Respirology, Neurology and Rheumatology, Kurume University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Andoh","sequence":"additional","affiliation":[{"name":"Department of Medicine, Shiga University of Medical Science"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1739","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Friedrich M, Pohin M, Powrie F. Cytokine networks in the pathophysiology of inflammatory bowel disease. Immunity 2019; 50: 992\u20131006.","DOI":"10.1016\/j.immuni.2019.03.017"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Andoh A, Yagi Y, Shioya M, Nishida A, Tsujikawa T, Fujiyama Y. Mucosal cytokine network in inflammatory bowel disease. World J Gastroenterol 2008; 14: 5154\u20135161.","DOI":"10.3748\/wjg.14.5154"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Bochkov YA, Hanson KM, Keles S, Brockman-Schneider RA, Jarjour NN, Gern JE. Rhinovirus-induced modulation of gene expression in bronchial epithelial cells from subjects with asthma. Mucosal Immunol 2010; 3: 69\u201380.","DOI":"10.1038\/mi.2009.109"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Nishida A, Hidaka K, Kanda T, et al. Increased expression of interleukin-36, a member of the interleukin-1 cytokine family, in inflammatory bowel disease. Inflamm Bowel Dis 2016; 22: 303\u2013314.","DOI":"10.1097\/MIB.0000000000000654"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Frey S, Derer A, Messbacher ME, et al. The novel cytokine interleukin-36\u03b1 is expressed in psoriatic and rheumatoid arthritis synovium. Ann Rheum Dis 2013; 72: 1569\u20131574.","DOI":"10.1136\/annrheumdis-2012-202264"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Mahil SK, Catapano M, Di Meglio P, et al. An analysis of IL-36 signature genes and individuals with <i>IL1RL2<\/i> knockout mutations validates IL-36 as a psoriasis therapeutic target. Sci Transl Med 2017; 9: eaan2514.","DOI":"10.1126\/scitranslmed.aan2514"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Scheibe K, Kersten C, Schmied A, et al. Inhibiting interleukin 36 receptor signaling reduces fibrosis in mice with chronic intestinal inflammation. Gastroenterology 2019; 156: 1082\u20131097.e11.","DOI":"10.1053\/j.gastro.2018.11.029"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Scheibe K, Backert I, Wirtz S, et al. IL-36R signalling activates intestinal epithelial cells and fibroblasts and promotes mucosal healing <i>in vivo<\/i>. Gut 2017; 66: 823\u2013838.","DOI":"10.1136\/gutjnl-2015-310374"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Madonna S, Girolomoni G, Dinarello CA, Albanesi C. The significance of IL-36 hyperactivation and IL-36R targeting in psoriasis. Int J Mol Sci 2019; 20: 3318.","DOI":"10.3390\/ijms20133318"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Towne JE, Garka KE, Renshaw BR, Virca GD, Sims JE. Interleukin (IL)-1F6, IL-1F8, and IL-1F9 signal through IL-1Rrp2 and IL-1RAcP to activate the pathway leading to NF-kappaB and MAPKs. J Biol Chem 2004; 279: 13677\u201313688.","DOI":"10.1074\/jbc.M400117200"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Kanda T, Nishida A, Takahashi K, et al. Interleukin(IL)-36\u03b1 and IL-36\u03b3 induce proinflammatory mediators from human colonic subepithelial myofibroblasts. Front Med (Lausanne) 2015; 2: 69.","DOI":"10.3389\/fmed.2015.00069"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Lin H, Ho AS, Haley-Vicente D, et al. Cloning and characterization of IL-1HY2, a novel interleukin-1 family member. J Biol Chem 2001; 276: 20597\u201320602.","DOI":"10.1074\/jbc.M010095200"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Bensen JT, Dawson PA, Mychaleckyj JC, Bowden DW. Identification of a novel human cytokine gene in the interleukin gene cluster on chromosome 2q12-14. J Interferon Cytokine Res 2001; 21: 899\u2013904.","DOI":"10.1089\/107999001753289505"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 van de Veerdonk FL, Stoeckman AK, Wu G, et al. IL-38 binds to the IL-36 receptor and has biological effects on immune cells similar to IL-36 receptor antagonist. Proc Natl Acad Sci U S A 2012; 109: 3001\u20133005.","DOI":"10.1073\/pnas.1121534109"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Xu WD, Huang AF. Role of interleukin-38 in chronic inflammatory diseases: a comprehensive review. Front Immunol 2018; 9: 1462.","DOI":"10.3389\/fimmu.2018.01462"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Mora J, Schlemmer A, Wittig I, et al. Interleukin-38 is released from apoptotic cells to limit inflammatory macrophage responses. J Mol Cell Biol 2016; 8: 426\u2013438.","DOI":"10.1093\/jmcb\/mjw006"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Mercurio L, Morelli M, Scarponi C, et al. IL-38 has an anti-inflammatory action in psoriasis and its expression correlates with disease severity and therapeutic response to anti-IL-17A treatment. Cell Death Dis 2018; 9: 1104.","DOI":"10.1038\/s41419-018-1143-3"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Han Y, Mora J, Huard A, et al. IL-38 Ameliorates skin inflammation and limits IL-17 production from \u03b3\u03b4 T cells. Cell Rep 2019; 27: 835\u2013846.e5.","DOI":"10.1016\/j.celrep.2019.03.082"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Takenaka SI, Kaieda S, Kawayama T, et al. IL-38: a new factor in rheumatoid arthritis. Biochem Biophys Rep 2015; 4: 386\u2013391.","DOI":"10.1016\/j.bbrep.2015.10.015"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ 1989; 298: 82\u201386.","DOI":"10.1136\/bmj.298.6666.82"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Best WR, Becktel JM, Singleton JW. Rederived values of the eight coefficients of the Crohn\u2019s Disease Activity Index (CDAI). Gastroenterology 1979; 77 (4 Pt 2): 843\u2013846.","DOI":"10.1016\/0016-5085(79)90384-6"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Matsuoka M, Kawayama T, Tominaga M, et al. Attenuated airway eosinophilic inflammations in IL-38 knockout mouse model. Kurume Med J 2019; 65: 37\u201346.","DOI":"10.2739\/kurumemedj.MS652009"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Seo SU, Kamada N, Mu\u00f1oz-Planillo R, et al. Distinct commensals induce interleukin-1\u03b2 via NLRP3 inflammasome in inflammatory monocytes to promote intestinal inflammation in response to injury. Immunity 2015; 42: 744\u2013755.","DOI":"10.1016\/j.immuni.2015.03.004"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Dinarello C, Arend W, Sims J, et al. IL-1 family nomenclature. Nat Immunol 2010; 11: 973.","DOI":"10.1038\/ni1110-973"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Dinarello CA. Introduction to the interleukin-1 family of cytokines and receptors: drivers of innate inflammation and acquired immunity. Immunol Rev 2018; 281: 5\u20137.","DOI":"10.1111\/imr.12624"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26 Xu WD, Su LC, He CS, Huang AF. Plasma interleukin-38 in patients with rheumatoid arthritis. Int Immunopharmacol 2018; 65: 1\u20137.","DOI":"10.1016\/j.intimp.2018.09.028"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27 Rudloff I, Godsell J, Nold-Petry CA, et al. Brief report: interleukin-38 exerts antiinflammatory functions and is associated with disease activity in systemic lupus erythematosus. Arthritis Rheumatol 2015; 67: 3219\u20133225.","DOI":"10.1002\/art.39328"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28 Ciccia F, Accardo-Palumbo A, Alessandro R, et al. Interleukin-36\u03b1 axis is modulated in patients with primary Sj\u00f6gren\u2019s syndrome. Clin Exp Immunol 2015; 181: 230\u2013238.","DOI":"10.1111\/cei.12644"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29 M\u00fcller A, Hennig A, Lorscheid S, et al. I\u03baB\u03b6 is a key transcriptional regulator of IL-36-driven psoriasis-related gene expression in keratinocytes. Proc Natl Acad Sci U S A 2018; 115: 10088\u201310093.","DOI":"10.1073\/pnas.1801377115"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30 W\u00e9ra O, Lancellotti P, Oury C. The dual role of neutrophils in inflammatory bowel diseases. J Clin Med 2016; 5: 118.","DOI":"10.3390\/jcm5120118"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31 Xie C, Yan W, Quan R, et al. Interleukin-38 is elevated in inflammatory bowel diseases and suppresses intestinal inflammation. Cytokine 2020; 127: 154963.","DOI":"10.1016\/j.cyto.2019.154963"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32 Kobori A, Yagi Y, Imaeda H, et al. Interleukin-33 expression is specifically enhanced in inflamed mucosa of ulcerative colitis. J Gastroenterol 2010; 45: 999\u20131007.","DOI":"10.1007\/s00535-010-0245-1"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33 Takahashi K, Imaeda H, Fujimoto T, et al. Regulation of eotaxin-3\/CC chemokine ligand 26 expression by T helper type 2 cytokines in human colonic myofibroblasts. Clin Exp Immunol 2013; 173: 323\u2013331.","DOI":"10.1111\/cei.12117"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34 Andoh A, Shioya M, Nishida A, et al. Expression of IL-24, an activator of the JAK1\/STAT3\/SOCS3 cascade, is enhanced in inflammatory bowel disease. J Immunol 2009; 183: 687\u2013695.","DOI":"10.4049\/jimmunol.0804169"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35 Boutet MA, Najm A, Bart G, et al. IL-38 overexpression induces anti-inflammatory effects in mice arthritis models and in human macrophages <i>in vitro<\/i>. Ann Rheum Dis 2017; 76: 1304\u20131312.","DOI":"10.1136\/annrheumdis-2016-210630"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36 Xie L, Huang Z, Li H, Liu X, Zheng S, Su W. IL-38: a new player in inflammatory autoimmune disorders. Biomolecules 2019; 9: 345.","DOI":"10.3390\/biom9080345"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37 Rosser EC, Mauri C. Regulatory B cells: origin, phenotype, and function. Immunity 2015; 42: 607\u2013612.","DOI":"10.1016\/j.immuni.2015.04.005"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38 Mizoguchi A, Mizoguchi E, Takedatsu H, Blumberg RS, Bhan AK. Chronic intestinal inflammatory condition generates IL-10-producing regulatory B cell subset characterized by CD1d upregulation. Immunity 2002; 16: 219\u2013230.","DOI":"10.1016\/S1074-7613(02)00274-1"}],"container-title":["Journal of Clinical Biochemistry and Nutrition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jcbn\/70\/1\/70_21-104\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T03:47:01Z","timestamp":1641008821000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jcbn\/70\/1\/70_21-104\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.3164\/jcbn.21-104","relation":{},"ISSN":["0912-0009","1880-5086"],"issn-type":[{"value":"0912-0009","type":"print"},{"value":"1880-5086","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022]]},"article-number":"21-104"}}